The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated
Open accessAbstract
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonly treated by inhibiting androgen action. However, androgen ablation or castration fail to target androgen-independent cells implicated in disease etiology and recurrence. Mechanistically different to castration, this study shows beneficial proapoptotic actions of estrogen receptor–β (ERβ) in BPH and PCa. ERβ agonist induces apoptosis in prostatic stromal, luminal and castrate-resistant basal epithelial cells of estrogen-deficient aromatase knock-out mice. This occurs via extrinsic (caspase-8) pathways, without reducing serum hormones, and perturbs the regenerative capacity of the epithelium. TNFα knock-out mice fail to respond to ERβ agonist, demonstrating the requirement for TNFα signaling. In human tissues, ERβ agonist induces apoptosis in stroma and epithelium of xenografted BPH specimens, including in the CD133+enriched putative stem/progenitor cells isolated from BPH-1 cells in vitro. In PCa, ERβ causes apoptosis in Gleason Grade 7 xenografted tissues and androgen-independent cells lines (PC3 and DU145) via caspase-8. These data provide evidence of the beneficial effects of ERβ agonist on epithelium and stroma of BPH, as well as androgen-independent tumor cells implicated in recurrent disease. Our data are indicative of the therapeutic potential of ERβ agonist for treatment of PCa and/or BPH with or without androgen withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, C. R., Graves, K. H., Parlow, A. F., & Simpson, E. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6965 · Cited by 867
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Cited by
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 721
Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature
Messina, M. (2016) · Nutrients · doi:10.3390/nu8120754 · Cited by 537
Cooke, P. S., Nanjappa, M. K., Ko, C., Prins, G. S., & Hess, R. A. (2017) · Physiological Reviews · doi:10.1152/physrev.00018.2016 · Cited by 466
Estrogen Receptors: Therapies Targeted to Receptor Subtypes
Nilsson, S., & Gustafsson, J.-Å. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.226 · Cited by 370
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Metadata
- Authors
- McPherson, S. J., Hussain, S., Balanathan, P., Hedwards, S. L., Niranjan, B., Grant, M., Chandrasiri, U. P., Toivanen, R., Wang, Y., Taylor, R. A., & Risbridger, G. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-02
- Volume
- 107
- Issue
- 7
- Pages
- 3123-3128
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2000524802
- Cited by
- 197
- References
- 2
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. https://app.cochat.ai/papers/10.1073/pnas.0905524107
- The paper
- McPherson, S. J., Hussain, S., Balanathan, P., Hedwards, S. L., Niranjan, B., Grant, M., Chandrasiri, U. P., Toivanen, R., Wang, Y., Taylor, R. A., & Risbridger, G. P. (2010). Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0905524107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.